Pediatric Cardiology

, Volume 34, Issue 7, pp 1620–1627

Implanted Defibrillators in Young Hypertrophic Cardiomyopathy Patients: A Multicenter Study

  • Anna N. Kamp
  • Nicholas H. Von Bergen
  • Charles A. Henrikson
  • Majd Makhoul
  • Elizabeth V. Saarel
  • Martin J. LaPage
  • Mark W. Russell
  • Margaret Strieper
  • Sunkyung Yu
  • Macdonald Dick
  • Sharlene M. Day
  • David J. Bradley
Original Article


Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, with an annual risk of sudden cardiac death (SCD) estimated at 1 %. Limited data are available regarding both the risk of SCD in the young HCM population and the use of implantable cardioverter-defibrillators (ICDs). This retrospective study included all patients with HCM who underwent ICD implantation for primary or secondary prevention of SCD before the age of 30 years at five institutions between 1995 and 2009. There were 99 devices implanted in 73 patients. Appropriate shocks occurred for 11 % of all the patients. None of the previously identified conventional risk factors for SCD in HCM patients were associated with increased risk of appropriate shocks in the young study cohort. During a median follow-up period of 2.4 years, inappropriate shocks occurred for 22 % of the patients. Older age at implant was associated with a decreased risk of inappropriate shock. Those who underwent implantation in the earlier decade had a higher incidence of inappropriate shocks. Late complications including lead fracture or dislodgement, generator malfunction, and infection occurred for 32 % of the patients. Three patients died (4 %), one of whom had an arrhythmic sudden death. A greater proportion of primary prevention implantations was performed for patients from the latter decade. Over time, ICD use in young HCM patients has become increasingly primary prevention oriented. Shock rates mirror those reported in adult series, and there is a substantial incidence of device complications.


Hypertrophic cardiomyopathy Implantable cardioverter-defibrillator Pediatric Young adult 


  1. 1.
    Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51:1369–1374CrossRefPubMedGoogle Scholar
  2. 2.
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMedGoogle Scholar
  3. 3.
    Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L (2003) Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. PACE 26:1887–1896CrossRefPubMedGoogle Scholar
  4. 4.
    Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, Cannon BC, Alexander ME, Triedman JK, Walsh EP, Friedman RA (2008) Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 51:1685–1691CrossRefPubMedGoogle Scholar
  5. 5.
    Blom NA (2008) Implantable cardioverter-defibrillators in children. PACE 31(Suppl 1):S32–S34CrossRefPubMedGoogle Scholar
  6. 6.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, Jacobs AK, Smith SC Jr, Anderson JL, Albert NM, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Krumholz HM, Kushner FG, Ohman EM, Page RL, Stevenson WG, Tarkington LG (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142:e153–e203CrossRefPubMedGoogle Scholar
  7. 7.
    Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W (2010) Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 122:1265–1271CrossRefPubMedGoogle Scholar
  8. 8.
    Lawrence D, Von Bergen N, Law IH, Bradley DJ, Dick M II, Frias PA, Streiper MJ, Fischbach PS (2009) Inappropriate ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult population. J Cardiovasc Electrophysiol 20:287–290CrossRefPubMedGoogle Scholar
  9. 9.
    Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E (2009) Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 30:2003–2010CrossRefPubMedGoogle Scholar
  10. 10.
    Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRefGoogle Scholar
  11. 11.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA (2009) Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 95:709–714CrossRefPubMedGoogle Scholar
  12. 12.
    Marian AJ (2010) Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 40:360–369PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–1320PubMedGoogle Scholar
  14. 14.
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMedGoogle Scholar
  15. 15.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405–412PubMedGoogle Scholar
  16. 16.
    Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ (2003) Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol 42:873–879CrossRefPubMedGoogle Scholar
  17. 17.
    Nannenberg EA, Michels M, Christiaans I, Majoor-Krakauer D, Hoedemaekers YM, van Tintelen JP, Lombardi MP, Ten Cate FJ, Schinkel AF, Tijssen JG, van Langen IM, Wilde AA, Sijbrands EJ (2011) Mortality risk of untreated Myosin-binding protein C-related hypertrophic cardiomyopathy: insight into the natural history. J Am Coll Cardiol 58:2406–2414CrossRefPubMedGoogle Scholar
  18. 18.
    O’Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, Al-Shaikh S, Rahman SM, Arnous S, Jones S, McKenna W, Elliott P (2012) The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 98:116–125CrossRefPubMedGoogle Scholar
  19. 19.
    Pablo Kaski J, Tome Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, McKenna WJ, Elliott PM (2007) Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 93:372–374CrossRefGoogle Scholar
  20. 20.
    Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96:2987–2991CrossRefPubMedGoogle Scholar
  21. 21.
    Silka MJ, Kron J, Dunnigan A, Dick M II (1993) Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The pediatric electrophysiology society. Circulation 87:800–807CrossRefPubMedGoogle Scholar
  22. 22.
    Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778–1785CrossRefPubMedGoogle Scholar
  23. 23.
    Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barilla CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119:1703–1710CrossRefPubMedGoogle Scholar
  24. 24.
    Suk T, Edwards C, Hart H, Christiansen JP (2008) Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ 17:370–374CrossRefPubMedGoogle Scholar
  25. 25.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczynska-Mazuruk R, Ruzyllo W, Szwed H (2010) Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 21:883–889PubMedGoogle Scholar
  26. 26.
    Von Bergen NH, Atkins DL, Dick M II, Bradley DJ, Etheridge SP, Saarel EV, Fischbach PS, Balaji S, Sreeram N, Evans WN, Law IH (2011) Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol 32:399–405CrossRefGoogle Scholar
  27. 27.
    Walsh EP (2008) Practical aspects of implantable defibrillator therapy in patients with congenital heart disease. PACE 31(Suppl 1):S38–S40CrossRefPubMedGoogle Scholar
  28. 28.
    Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H (2010) DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 31:926–935CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Anna N. Kamp
    • 1
  • Nicholas H. Von Bergen
    • 2
  • Charles A. Henrikson
    • 3
    • 4
  • Majd Makhoul
    • 5
  • Elizabeth V. Saarel
    • 6
  • Martin J. LaPage
    • 7
  • Mark W. Russell
    • 7
  • Margaret Strieper
    • 5
  • Sunkyung Yu
    • 7
  • Macdonald Dick
    • 7
  • Sharlene M. Day
    • 7
    • 8
  • David J. Bradley
    • 7
  1. 1.MN150 Chandler Medical CenterUniversity of KentuckyLexingtonUSA
  2. 2.UI Children’s Hospitals Pediatric Specialty ClinicsUniversity of IowaIowa CityUSA
  3. 3.Johns HopkinsBaltimoreUSA
  4. 4.Division of Cardiovascular Medicine, MC UHN-62Oregon Health & Science UniversityPortlandUSA
  5. 5.Sibley Heart Center CardiologyEmory UniversityAtlantaUSA
  6. 6.University of UtahSalt Lake CityUSA
  7. 7.CS Mott Children’s Hospital Floor 11 Room 661University of MichiganAnn ArborUSA
  8. 8.Cardiovascular Center 1500 East Medical Center DriveAnn ArborUSA

Personalised recommendations